Detail akcie Cerus Corp online

Business Summary: Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Cerus Corp revenues increased 23% to $59.9M. Net loss decreased 79% to $1.6M. Revenues reflect North America segment increase of 20% to $36.8M, Europe and Middle East and Africa segment increase of 28% to $15.7M, Other segment increase from $427K to $1.2M. Lower net loss reflects Blood Safety segment loss decrease of 94% to $354K.